Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 6.65% is 50% below its 5-year average of 13.40%, near the low end of its 5-year range (6.08%–20.29%).
As of the fiscal period ended Tuesday, June 30, 2026. 5.18% below its 12-month average of 7.02%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 6.65%.
RETURN ON EQUITY (ROE)
6.65%
RETURN ON EQUITY (ROE) AVG TTM
7.02%
RETURN ON EQUITY (ROE) AVG 3Y
10.43%
RETURN ON EQUITY (ROE) AVG 5Y
13.40%
RETURN ON EQUITY (ROE) AVG 10Y
15.74%
RETURN ON EQUITY (ROE) AVG 15Y
15.08%
RETURN ON EQUITY (ROE) AVG 20Y
15.55%
CURRENT VS TTM AVG
-5.18%
CURRENT VS 3Y AVG
-36.22%
CURRENT VS 5Y AVG
-50.37%
CURRENT VS 10Y AVG
-57.73%
CURRENT VS 15Y AVG
-55.89%
CURRENT VS 20Y AVG
-57.24%
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
-48.87%
vs the sector median at left
Humana Inc.
Market Cap
$49.21B
Return on Equity (ROE)
6.65%
TTM Avg
7.02%
3Y Avg
10.43%
5Y Avg
13.40%
Market Cap
$49.00B
Return on Equity (ROE)
3.85%
TTM Avg
6.60%
3Y Avg
6.50%
5Y Avg
6.42%
Market Cap
$48.58B
Return on Equity (ROE)
9.46%
TTM Avg
26.07%
3Y Avg
24.86%
5Y Avg
23.86%
Market Cap
$54.94B
Return on Equity (ROE)
N/A
TTM Avg
-57.79%
3Y Avg
-38.31%
5Y Avg
2.19%
Market Cap
$43.20B
Return on Equity (ROE)
9.10%
TTM Avg
-6.34%
3Y Avg
-12.86%
5Y Avg
-14.53%
Market Cap
$43.09B
Return on Equity (ROE)
22.28%
TTM Avg
21.77%
3Y Avg
21.17%
5Y Avg
17.55%
Market Cap
$41.50B
Return on Equity (ROE)
19.56%
TTM Avg
20.59%
3Y Avg
21.51%
5Y Avg
20.54%
Market Cap
$57.13B
Return on Equity (ROE)
-46.61%
TTM Avg
-32.64%
3Y Avg
-13.90%
5Y Avg
0.25%
Market Cap
$39.81B
Return on Equity (ROE)
70.67%
TTM Avg
60.82%
3Y Avg
72.53%
5Y Avg
81.69%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Humana Inc. (HUM) | $49.21B | 6.65% | 7.02% | 10.43% | 13.40% |
| Becton, Dickinson and Company (BDX)vs › | $49.00B | 3.85% | 6.60% | 6.50% | 6.42% |
| Edwards Lifesciences Corporation (EW)vs › | $48.58B | 9.46% | 26.07% | 24.86% | 23.86% |
| Cardinal Health, Inc. (CAH)vs › | $54.94B | N/A | -57.79% | -38.31% | 2.19% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $43.20B | 9.10% | -6.34% | -12.86% | -14.53% |
| IQVIA Holdings Inc. (IQV)vs › | $43.09B | 22.28% | 21.77% | 21.17% | 17.55% |
| Agilent Technologies, Inc. (A)vs › | $41.50B | 19.56% | 20.59% | 21.51% | 20.54% |
| Moderna, Inc. (MRNA)vs › | $57.13B | -46.61% | -32.64% | -13.90% | 0.25% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $39.81B | 70.67% | 60.82% | 72.53% | 81.69% |
| Cencora, Inc. (COR)vs › | $62.57B | 86.03% | 168.34% | -32.99% | 148.52% |
ROE
6.7%
ROA
2.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 6.65% |
| 2026-03-31 | 6.08% |
| 2025-12-31 | 6.73% |
| 2025-09-30 | 6.97% |
| 2025-06-30 | 8.64% |
| 2025-03-31 | 9.63% |
| 2024-12-31 | 7.37% |
| 2024-09-30 | 7.74% |
| 2024-06-30 | 10.26% |
| 2024-03-31 | 12.34% |
| 2023-12-31 | 15.31% |
| 2023-09-30 | 17.79% |
| 2023-06-30 | 20.07% |
| 2023-03-31 | 18.79% |
| 2022-12-31 | 18.33% |
| 2022-09-30 | 17.27% |
| 2022-06-30 | 20.29% |
| 2022-03-31 | 19.81% |
| 2021-12-31 | 18.24% |
| 2021-09-30 | 16.44% |
| 2021-06-30 | 16.72% |
| 2021-03-31 | 26.23% |
| 2020-12-31 | 24.53% |
| 2020-09-30 | 26.34% |
| 2020-06-30 | 24.29% |
| 2020-03-31 | 21.16% |
| 2019-12-31 | 22.49% |
| 2019-09-30 | 21.98% |
| 2019-06-30 | 21.10% |
| 2019-03-31 | 16.22% |
| 2018-12-31 | 16.56% |
| 2018-09-30 | 14.27% |
| 2018-06-30 | 13.39% |
| 2018-03-31 | 18.09% |
| 2017-12-31 | 24.87% |
| 2017-09-30 | 16.62% |
| 2017-06-30 | 16.56% |
| 2017-03-31 | 14.41% |
| 2016-12-31 | 5.75% |
| 2016-09-30 | 9.89% |
| 2016-06-30 | 9.01% |
| 2016-03-31 | 10.45% |
| 2015-12-31 | 12.33% |
| 2015-09-30 | 12.75% |
| 2015-06-30 | 12.85% |
| 2015-03-31 | 12.04% |
| 2014-12-31 | 11.89% |
| 2014-09-30 | 9.60% |
| 2014-06-30 | 10.50% |
| 2014-03-31 | 11.58% |
| 2013-12-31 | 13.21% |
| 2013-09-30 | 15.13% |
| 2013-06-30 | 16.19% |
| 2013-03-31 | 15.79% |
| 2012-12-31 | 13.81% |
| 2012-09-30 | 14.14% |
| 2012-06-30 | 14.76% |
| 2012-03-31 | 16.42% |
| 2011-12-31 | 17.60% |
| 2011-09-30 | 16.89% |
| 2011-06-30 | 16.81% |
| 2011-03-31 | 15.99% |
| 2010-12-31 | 15.88% |
| 2010-09-30 | 17.91% |
| 2010-06-30 | 17.77% |
| 2010-03-31 | 17.96% |
| 2009-12-31 | 18.00% |
| 2009-09-30 | 17.36% |
| 2009-06-30 | 16.70% |
| 2009-03-31 | 16.54% |
| 2008-12-31 | 14.52% |
| 2008-09-30 | 16.77% |
| 2008-06-30 | 19.88% |
| 2008-03-31 | 20.79% |
| 2007-12-31 | 20.69% |
| 2007-09-30 | 19.94% |
| 2007-06-30 | 17.84% |
| 2007-03-31 | 15.03% |
| 2006-12-31 | 15.96% |
| 2006-09-30 | 13.73% |
| 2006-06-30 | 10.70% |
| 2006-03-31 | 10.77% |
| 2005-12-31 | 12.11% |
| 2005-09-30 | 11.92% |
| 2005-06-30 | 13.80% |
| 2005-03-31 | 14.50% |
| 2004-12-31 | 13.40% |
| 2004-09-30 | 14.80% |
| 2004-06-30 | 14.48% |
| 2004-03-31 | 13.91% |
| 2003-12-31 | 12.47% |
| 2003-09-30 | 9.15% |
| 2003-06-30 | 8.86% |
